Time released theophylline for chronotheraputic treatment of nocturnal asthma
Keywords:
chronotherapy, nocturnal asthma, Eudragit S, Film coating, Beagle dogsAbstract
The aim of this work is designing and evaluation of chronotherapeutic dosage form of theophylline (TPH). Film coated tablets were formulated using an Eudragit S-100 based coating formula as time released system and optimized toward a prospective control of nocturnal asthma. Core tablets, containing 200 mg TPH, were formulated by wet granulation process. Different formulae F1, F2, F3 and F4 were prepared by film coating to percentage weight gain of 5%, 10%, 15%, and 20%, respectively. The in vitro release profiling test was done in variant pH media with certain order mimicking GIT media (pH 1.2, 6, 7.5 and 6.8). The in vivo performance of the optimum formula was compared with Avolen® SR, a marketed generic sustained release TPH tablets, in beagle dogs. The results clearly showed the criticality of film thickness in the performance of the coat and its function. F1 and F2 failed to protect TPH tablet in the acidic pH media, while both F3 and F7 showed lag time of release 4 and 5 hours, respectively. F4 exhibited only 52.9% cumulative drug release along the 9 hours dissolution period. The Cmax values were found to be 5.49 ± 0.46 and 5.12 ± 0.85 μg/ml for F3 and Avolen® SR, respectively, F3 showed higher mean plasma concentration than Avolen® SR from the period 1.5 till 5.5 hours post administration indicating high potential as chronotherapeutic treatment of nocturnal asthma.
References
molensky M, Labrecque G. Chronotherapeutics. Pharmcaceutical News 1997; 4: 10-16.
Sydenham T, editor. The Works of Thomas Sydenham MD, Translated from the Latin by Lathan RG, vol. 2. London, England: The Sydenham Society; 1850. p 124.
Moore J, Halberg F. Circadian rhythm of gastric acid secretion in active duodenal ulcer: chronobiological statistical characteristics and comparison of acid secretory and plasma gastrin patterns in healthy and post-vagotomy and pyloroplasty patients. Chronobiol. Int. 1987; 4: 101–110.
Bateman J, Clark S. Sudden death in asthma. Thorax.1979; 34: 40–44.
Cugini P, Di Palma L, Battisti P, Leone G, Materia E, Parenzi A, Romano M, Ferrera U, Moretti M. Ultradian, circadian and infradian periodicity of some cardiovascular emergencies. Am. J. Cardiol. 1990; 66: 240–243.
Kowanko I, Knapp M, Pownall R, Swannell A. Domiciliary self measurement in rheumatoid arthritis and the demonstration of circadian rhythmicity. Ann Rheum Dis. 1982; 41: 453–455.
Kelmanson I. Circadian variation of the frequency of sudden infant death syndrome and of sudden death from life-threatening conditions in infants. Chronobiologia. 1991; 18: 181–186.
Smolensky M, Reinberg A, Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Immunol. 1995; 95: 1084–1096.
Manfredini R, Gallerani M, Salmi R, Calò G, Pasin M, Bigoni M, Fersini C. Circadian variation in the time of onset of acute intestinal bleeding. J Emerg Med. 1994; 12: 5–9.
Skloot G. Nocturnal asthma. The Mount Sinai Journal of Medicine. 2002; 69(3): 140-147.
Neuenkirchen H, Wilkens J, Oellerich M, Sybrecht G. Nocturnal asthma: effect of a once per evening dose of sustained-release theophylline. Eur J Respir Dis. 1985; 66: 196–204.
Robertson C, Rubinfeld A, Bowej G. Deaths from asthma in Victoria: a 12-month study. Med J Austr.1990; 152: 511- 517.
Smolensky M. Chronobiology and chronotherapeutics: Applications to cardiovascular medicine. Am J Hypertens. 1996; 9: 11S-21S.
D'Alonzo G, Smolensky M, Feldman S, Gianotti L, Emerson M, Staudinger H, Steinijan V. Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis. 1990; 142: 84–90.
Reinberg A, Gervais P, Chaussade M, Fraboulet G, Duburque B. Circadian changes in effectiveness of corticosteroids in eight patients with allergic asthma. J Allergy Clin Immunol. 1983; 71: 425-433.
Kinget R, Kalala W, Vervoort L, van denMooter G. Colonic drug targeting. J Drug Target. 1998; 6: 129-149.
Dew M, Hughes P, Lee M, Evans B, Rhodes J. An oral preparation to release drugs in the human colon. British Journal of Clinical Pharmacology. 1982; 14: 405–408.
Klotz U, Maier K, Fischer C, Bauer K. A new slow-release form of 5-amino salicylic acid for the oral treatment of inflammatory bowel disease: Biopharmaceutical and pharmaceutical characteristics. Drug Res. 1985; 35: 636-639.
Touitou E, Rubinstein A. Targeted enteral delivery of insulin to rats. Int J Pharm. 1986; 30: 95-99.
Barakat N, Al-Suwayeh S, Taha E, Yassin A. A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma. 2011; 19(5): 365-372.
Huyghebaert N, Vermeire N, Remon J. In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J of Pharm. 2005; 298: 26-37.
Rogge M, Solomon W, Sedman A, Welling P, Toothaker R, Wagner J. The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. 1988; Clin Pharmacol Ther, 1988; 44: 579–587.
Rojanasthien N, Kovjiriyapan K, Manorot M, Pothirat C. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Asian Pac J Allergy Immunol. 2001; 19(2): 69-78.
Trevor A, Katzung B, Masters A, editors.. Pharmacology Examination and Board Review, 6th ed. North America: The McGraw-Hill Companies Inc.; 2002. P.187.
Alvarez-Fuentes J, Fernández-Arévalo M, González-Rodríguez M, Cirri M, Mura P. Development of enteric-coated timed-release matrix tablets for colon targeting. J Drug Target. 2004; 12(9-10): 607- 612.
DiLuccio R, Hussain M, Coffin-Beach D, Torosian G, Shefter E, Hurwitz A. Sustained-release oral delivery of theophylline by use of polyvinyl alcohol and polyvinyl alcohol-methyl acrylate polymers. J Pharm Sci. 1994; 83(1): 104-106.
Tatsis G, Tsoukalas G, Peristerakis A, Filaditaki V, Orfanidou D, Anagnostou E. Bioavailability of a new sustained-release anhydrous theophylline product. J Int Med Res. 1996; 24(4): 331-339.
Tulain U, Ur-Rahman N. Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline tablets and pellets. Pak J Pharm Sci. 1996; 21( 2):131-138.
Weinbereger M, Hendeles L, Bighley L. The relation of product formulation to absorption of oral theophylline. N Engl J Med. 1978; 299: 852-57.
Weinberger M, Hendeles L, Wong L, Vaughan L. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma. J Pediatr. 1981; 99: 145- 52.
Hendeles L, Ifrate P, Weinberger M. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinetic. 1984; 9: 95-135.
Hendeles L, Massanari M, Weinbergen M. Update on the pharmacodynamic and pharmacokinetics of theophylline. Chest. 1985; 88: 103-111.
